Taiwan Bio Therapeutics Co., Ltd.(TW:6892)
NT$26.00-0.05 (-0.19%)
TW:6892
Taiwan Bio Therapeutics Co., Ltd. financials statements
NT$26.00
At close:-0.05 (-0.19%)
Taiwan Bio Therapeutics Co., Ltd. (6892) Ratios
Taiwan Bio Therapeutics Co., Ltd. Ratios
TW:6892's free cash flow for Q2 2025 was NT$-59.74M. For the 2025 fiscal year, TW:6892's free cash flow was decreased by NT$-11.35M and operating cash flow was NT$-48.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.01 | 10.16 | 5.41 | 5.38 | 1.92 |
| Quick Ratio | 3.67 | 9.75 | 4.74 | 4.83 | 1.79 |
| Cash Ratio | 3.15 | 8.75 | 4.03 | 4.34 | 1.42 |
| Solvency Ratio | -0.41 | -0.66 | -0.46 | -0.39 | -0.18 |
| Operating Cash Flow Ratio | -2.30 | -3.26 | -2.70 | -2.47 | -1.41 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ -255.77M | NT$ 405.64M | NT$ 4.71M | NT$ -39.74M | NT$ -252.84M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.21 | 0.29 | 0.33 | 0.49 |
| Debt-to-Equity Ratio | 0.44 | 0.29 | 0.44 | 0.54 | 1.14 |
| Debt-to-Capital Ratio | 0.30 | 0.22 | 0.30 | 0.35 | 0.53 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.86 | 1.35 | 1.54 | 1.65 | 2.30 |
| Debt Service Coverage Ratio | -36.70 | -47.45 | -27.50 | -23.99 | -20.45 |
| Interest Coverage Ratio | -54.38 | -67.40 | -39.98 | -33.69 | -30.57 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.85 | 4.31 | 4.80 | 5.87 | 9.89 |
| Net Debt to EBITDA | -0.11 | 1.46 | -0.14 | -0.31 | -3.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 63.74% | 53.35% | 89.34% | 70.77% | 83.39% |
| EBIT Margin | -764.16% | -329.79% | -248.28% | -408.09% | -321.61% |
| EBITDA Margin | -515.57% | -235.40% | -170.79% | -289.34% | -215.18% |
| Operating Profit Margin | -764.16% | -334.41% | -248.28% | -408.09% | -321.61% |
| Pretax Profit Margin | -756.75% | -334.75% | -254.49% | -420.20% | -332.13% |
| Net Profit Margin | -756.85% | -334.75% | -254.49% | -421.41% | -332.13% |
| Continuous Operations Profit Margin | -756.85% | -334.75% | -254.49% | -421.41% | -332.13% |
| Net Income Per EBT | 100.01% | 100.00% | 100.00% | 100.29% | 100.00% |
| EBT Per EBIT | 99.03% | 100.10% | 102.50% | 102.97% | 103.27% |
| Return on Assets (ROA) | -28.17% | -23.90% | -23.10% | -21.65% | -15.28% |
| Return on Equity (ROE) | -52.31% | -32.23% | -35.47% | -35.79% | -35.17% |
| Return on Capital Employed (ROCE) | -30.52% | -25.20% | -24.11% | -22.42% | -15.93% |
| Return on Invested Capital (ROIC) | -29.68% | -24.66% | -23.62% | -22.01% | -15.45% |
| Return on Tangible Assets | -40.06% | -25.31% | -24.78% | -21.75% | -15.35% |
| Earnings Yield | -15.82% | -11.27% | -11.32% | -12.44% | -8.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.30 | 2.64 | 3.54 | 9.72 | 3.66 |
| Payables Turnover | 3.27 | 23.54 | 2.11 | 1.28 | 1.73 |
| Inventory Turnover | 0.59 | 1.56 | 0.22 | 0.42 | 0.81 |
| Fixed Asset Turnover | 0.09 | 0.19 | 0.17 | 0.09 | 0.06 |
| Asset Turnover | 0.04 | 0.07 | 0.09 | 0.05 | 0.05 |
| Working Capital Turnover Ratio | 0.10 | 0.21 | 0.33 | 0.31 | -1.14 |
| Cash Conversion Cycle | 559.03 | 356.37 | 1571.52 | 610.95 | 337.34 |
| Days of Sales Outstanding | 50.01 | 138.46 | 103.07 | 37.54 | 99.70 |
| Days of Inventory Outstanding | 620.49 | 233.42 | 1641.08 | 859.18 | 448.58 |
| Days of Payables Outstanding | 111.47 | 15.51 | 172.62 | 285.77 | 210.94 |
| Operating Cycle | 670.50 | 371.88 | 1744.15 | 896.72 | 548.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.51 | -3.39 | -2.92 | -2.81 | -1.99 |
| Free Cash Flow Per Share | -2.89 | -4.88 | -5.01 | -4.49 | -7.87 |
| Dividend Paid and CapEx Coverage Ratio | -6.61 | -2.28 | -1.40 | -1.68 | -0.34 |
| Capital Expenditure Coverage Ratio | -6.61 | -2.28 | -1.40 | -1.68 | -0.34 |
| Operating Cash Flow Coverage Ratio | -0.67 | -0.80 | -0.62 | -0.49 | -0.20 |
| Operating Cash Flow to Sales Ratio | -4.21 | -2.40 | -1.95 | -3.13 | -2.18 |
| Free Cash Flow Yield | -10.13% | -11.64% | -14.87% | -14.72% | -21.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.32 | -8.88 | -8.83 | -8.04 | -12.02 |
| Price-to-Sales (P/S) Ratio | 47.83 | 29.71 | 22.48 | 33.88 | 39.87 |
| Price-to-Book (P/B) Ratio | 3.31 | 2.86 | 3.13 | 2.88 | 4.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.87 | -8.59 | -6.72 | -6.79 | -4.63 |
| Price-to-Operating Cash Flow Ratio | -11.36 | -12.37 | -11.54 | -10.83 | -18.30 |
| Price-to-Earnings Growth (PEG) Ratio | 1.42 | -0.37 | -16.74 | -0.32 | 0.71 |
| Enterprise Value Multiple | -9.39 | -11.16 | -13.30 | -12.02 | -22.49 |
| Enterprise Value | 2.44B | 2.76B | 1.94B | 1.56B | 1.31B |
| EV to EBITDA | -9.39 | -11.16 | -13.30 | -12.02 | -22.49 |
| EV to Sales | 48.39 | 26.26 | 22.72 | 34.79 | 48.40 |
| EV to Free Cash Flow | -9.98 | -7.60 | -6.80 | -6.97 | -5.62 |
| EV to Operating Cash Flow | -11.49 | -10.94 | -11.66 | -11.12 | -22.22 |
| Tangible Book Value Per Share | 3.87 | 13.55 | 10.32 | 10.51 | 8.54 |
| Shareholders’ Equity Per Share | 8.62 | 14.65 | 10.74 | 10.59 | 8.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.60 | 1.41 | 1.50 | 0.90 | 0.91 |
| Net Income Per Share | -4.51 | -4.72 | -3.81 | -3.79 | -3.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 1.02 | 1.03 | 1.03 | 1.03 |
| Research & Development to Revenue | 5.58 | 3.29 | 2.86 | 4.06 | 3.41 |
| SG&A to Revenue | 0.30 | 0.59 | 0.54 | 0.82 | 0.63 |
| Stock-Based Compensation to Revenue | 0.20 | 0.14 | 0.11 | 0.28 | 0.27 |
| Income Quality | 0.56 | 0.72 | 0.77 | 0.74 | 0.66 |
Currency in TWD
